Adial Pharmaceuticals, Inc.
AZR Nasdaq· Pharmaceutical Preparations
Last close · Nov 9, 2026
$3.75
Latest quarter · Q2 '26 results quarter ended Jun 30, 2026 · vs Q2 '25
| Line | Q2 '25 | Q2 '26 | Change (y/y) |
|---|---|---|---|
| Net income | −$2.0M | −$52.0M | — |
| Diluted EPS | −$4.61 | −$11.25 | — |
Fiscal 2026 so far (2 quarters) vs a year earlier
| Net income | −$54.0M | |
| Diluted EPS | −$12.73 |
Key numbers, fiscal 2025
Market cap
$17.3M
P/E
—
Revenue
—
Net income
−$8.0M
Free cash flow
—
Operating margin
—
Adial Pharmaceuticals, Inc. in 30 seconds fiscal 2025
Does it make a profit?
−$8.0M
No. It lost money last year.
How long would its cash last?
2.6 yrs
Comfortably. It burns $11.1M a year and holds $28.7M, about 2.6 years at that pace.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Adial Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Legal name
- Azora Therapeutics, Inc. (DE)
- CIK
- 0001513525
Adial Pharmaceuticals, Inc. · AZR · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$19.4M | −$12.7M | −$5.1M | −$13.2M | −$8.0M |
| Diluted EPS | −$1.04 | −$12.71 | −$3.60 | −$68.01 | −$11.93 |
| Cash | |||||
| Cash from operations | −$11.9M | −$11.2M | −$6.8M | −$6.9M | −$6.5M |
| Capital expenditure | $0.1M | — | — | — | — |
| Free cash flow | −$12.0M | — | — | — | — |
| Share buybacks | — | — | $0.0M | — | — |
| Share count change | 49.1% | −94.6% | 42.3% | −86.4% | 244.5% |
| Debt and strength | |||||
| Cash and short-term investments | $6.1M | $4.0M | $2.8M | $3.8M | $5.9M |
| Shareholders' equity | $3.5M | $3.3M | $4.1M | $4.1M | $5.3M |
| Current ratio | 2.4x | 2.7x | 4.9x | 4.2x | 4.4x |
| Returns and quality | |||||
| Return on equity | −518.4% | −375.3% | −139.2% | −323.8% | −170.7% |
| Return on tangible equity | −596.9% | −421.2% | −125.6% | −324.7% | −151.3% |
| Altman Z'' | −35.3 | −44.1 | −47.0 | −55.6 | −43.1 |
Insider trades 12 months
Insiders bought, 12 months
$0.1M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Adial Pharmaceuticals, Inc. · AZR · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001513525). Latest version: stoqly.net/companies/azr. Data updated November 9, 2026. For information only — not investment advice. Check the original filings before relying on any figure.